Neupulse is the brand of Neurotherapeutics Ltd. The direction of our current research was very much shaped by the feedback we received from individuals with tic disorders and their families. When we asked them for their thoughts on our research priorities we were frequently told that what was really needed was a safe and effective non-drug treatment for tic disorder that could be used outside of the clinic and gave individuals control over their tics. This led directly to us focusing on the use of peripheral nerve stimulation as a means of bringing about changes in the brain networks associated with the production of tics. We demonstrated that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist could be used to increase the power and the synchronicity of the brain oscillations (rhythms) associated with the suppression of movements, and that this type of stimulation was sufficient to dramatically reduce the frequency of tics and remove the urge-to-tic in individuals with tic disorders. Importantly, we also showed that this type of stimulation did not materially affect the execution of volitional (intentional) movements or impair cognitive functions such as attention.
| Website | https://neupulse.co |
| Employees | 20 (12 on RocketReach) |
| Founded | 2021 |
| Address | Triumph Road, The Ingenuity Centre, Nottingham, England NG7 2TU, GB |
| Industry | Hospitals and Health Care |
| Keywords | Neuromodulation, Tourette Syndrome, Neurotechnology, Movement Disorders, Brain Stimulation, Neurological Disorders, Treatment Solutions, Nervous System, Drug Delivery, Innovative Therapies, Therapeutic Devices, Clinical Trials, Patient Care, Medical Devices, Biomedical Research, Research And Development, Neuroscience, Healthcare Technology, Brain Health |
Looking for a particular Neupulse employee's phone or email?
Paul Cable is the CEO of Neupulse.
12 people are employed at Neupulse.
Neupulse is based in Nottingham, England.